ABOzymes Completes Seed Financing Round to Fund Development of Technology to Enable Universal Organ Transplants and Blood Transfusions

OBIO News
Written By Arsheen Kaur

ABOzymes Biomedical Inc., a B.C.-based preclinical stage, recently announced completing seed financing round to develop its breakthrough, proprietary platform that enables a world where a person’s blood type is no longer the first constraint during organ transplants and blood transfusions.

ABOzymes presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Increasing the Adoption of Canadian Innovations and Focusing on Women’s Leadership/Accroître l’adoption des innovations canadiennes et mettre à l’honneur le leadershipdes femmes
Next

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1